On this regard, PD1/PD-L1 blockers are promising adjuvant drugs [24], and accordingly in August 2016 the FDA approved pembrolizumab (Keytruda®) for the treatment of patients with an advanced form of head and neck cancer. This evidence concerns the gene CD274 and head and neck cancer.